| |
• Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilized, light-sensitive antibody-drug-conjugates (ADCs);
• It offers reliable light protection at the primary packaging level, already during the fill-and-finish process;
• EVERIC® amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan.
In combination with the hydrophobic inner coating EVERIC® lyo, the vial is ideally suited for lyophilized, highly light-sensitive medications, particularly next-generation antibody-drug-conjugates (ADCs) used in targeted cancer therapies.
“ADCs are among the most promising innovations in today’s biologics pipeline. We are proud to introduce another high-value solution that protects these sensitive therapies from the very beginning of the process”, says Andreas Reisse, CEO of SCHOTT Pharma. “This launch marks another important step in our commitment to enabling the safe delivery of complex biologics and to shaping the future of pharmaceutical packaging through innovation.”
EVERIC® lyo & amber addresses the growing need for light protection at the primary packaging level, ensuring the integrity of sensitive drugs already during filling. With its hydrophobic inner surface, it offers a lotus effect for efficient drug manufacturing and use and sets a new benchmark for ADCs that require lyophilization. Manufactured with precisely controlled light transmission properties, this vial is the first on the market that meets all regulatory light transmission requirements across major Pharmacopoeias in Europe, the United States, and Japan.
The new product will be on display at Pharmapack Paris, January 21-22 (hall 4, booth G38).
Targeted protection for one of the most promising drug classes in oncology
ADCs are among the most innovative drug classes in modern oncology. By combining targeted antibodies with highly potent cytotoxic agents, they enable precise cancer treatments with reduced side effects. At the same time, ADCs rank among the most complex, sensitive, and costly pharmaceuticals on the market. Some of these therapies are particularly sensitive to light, which can compromise their stability, efficacy, and shelf life. Ensuring reliable light protection throughout the entire product lifecycle is therefore critical.
Several ADCs currently approved or in clinical development show light sensitivity as early as the filling stage. Traditional secondary packaging is no longer sufficient to safeguard these drug products. Instead, a specialized primary packaging solution is required that delivers consistent and certified light protection from the outset.
EVERIC® lyo & amber: Designed for lyophilized ADCs
With EVERIC® amber, SCHOTT Pharma extends its proven specialty vial platform to include high-quality FIOLAX® amber borosilicate glass. The vials are manufactured using a precisely controlled hot-forming process. Specialized converting configurations enable tight dimensional tolerances and targeted light transmission adjustment, ensuring the level of protection required for light‑sensitive medications.
For lyophilized ADCs, the hydrophobic inner coating EVERIC® lyo offers added value by reducing both product loss and process risk. It minimizes fogging during lyophilization and improves residual emptying, making it particularly effective for preserving expensive and sensitive drug formulations. The coating is applied using SCHOTT Pharma’s patented PICVD technology, forming a covalent bond with the glass surface. Unlike siliconized vials, this process eliminates the risk of free silicone contamination in the drug.
Two in-production release criteria, documented in the Certificate of Analysis (CoA) ensure consistent quality and regulatory compliance of EVERIC® lyo & amber vials.
“With this innovation, we’re offering pharmaceutical companies a drug containment solution that meets the specific requirements of next-generation ADCs from the filling line all the way to the patient”, says Diana Löber, Global Product Manager at SCHOTT Pharma.
Like all vials in the EVERIC® portfolio, EVERIC® lyo & amber is modular and customizable and is manufactured exclusively at SCHOTT Pharma’s German site in Müllheim.
About SCHOTT Pharma
Human health matters. That is why SCHOTT Pharma (schott-pharma.com) designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment.
|
lea.kaiser[.]schott.com 
